Hmdb loader
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2021-09-11 00:32:22 UTC
Update Date2021-09-26 22:57:17 UTC
HMDB IDHMDB0247534
Secondary Accession NumbersNone
Metabolite Identification
Common NameN-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide
DescriptionN-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide, also known as C6-NBD-cer or 6-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminocaproylsphingosine, belongs to the class of organic compounds known as ceramides. These are lipid molecules containing a sphingosine in which the amine group is linked to a fatty acid. Based on a literature review very few articles have been published on N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide. This compound has been identified in human blood as reported by (PMID: 31557052 ). N-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources.
Structure
Thumb
Synonyms
ValueSource
6-N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)aminocaproylsphingosineHMDB
C6-NBD-CerHMDB
C6-NBD-CeramideHMDB
N-(7-(4-Nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosineHMDB
NBD C6-CerHMDB
NBD-CeramideHMDB
Chemical FormulaC30H49N5O6
Average Molecular Weight575.751
Monoisotopic Molecular Weight575.368284318
IUPAC NameN-(1,3-dihydroxyoctadec-4-en-2-yl)-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanamide
Traditional NameN-(1,3-dihydroxyoctadec-4-en-2-yl)-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanamide
CAS Registry NumberNot Available
SMILES
CCCCCCCCCCCCCC=CC(O)C(CO)NC(=O)CCCCCNC1=CC=C(C2=NON=C12)[N+]([O-])=O
InChI Identifier
InChI=1S/C30H49N5O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-27(37)25(23-36)32-28(38)19-16-14-17-22-31-24-20-21-26(35(39)40)30-29(24)33-41-34-30/h15,18,20-21,25,27,31,36-37H,2-14,16-17,19,22-23H2,1H3,(H,32,38)
InChI KeyHZIRBXILQRLFIK-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as ceramides. These are lipid molecules containing a sphingosine in which the amine group is linked to a fatty acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSphingolipids
Sub ClassCeramides
Direct ParentCeramides
Alternative Parents
Substituents
  • Ceramide
  • Benzoxadiazole
  • Nitroaromatic compound
  • Secondary aliphatic/aromatic amine
  • Fatty amide
  • N-acyl-amine
  • Fatty acyl
  • Benzenoid
  • Azole
  • Furazan
  • Heteroaromatic compound
  • Oxadiazole
  • Amino acid or derivatives
  • Carboxamide group
  • C-nitro compound
  • Organic nitro compound
  • Secondary alcohol
  • Secondary carboxylic acid amide
  • Organoheterocyclic compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic 1,3-dipolar compound
  • Secondary amine
  • Carboxylic acid derivative
  • Organic oxoazanium
  • Azacycle
  • Organic nitrogen compound
  • Alcohol
  • Hydrocarbon derivative
  • Organic oxide
  • Organopnictogen compound
  • Organonitrogen compound
  • Amine
  • Carbonyl group
  • Organooxygen compound
  • Organic oxygen compound
  • Organic zwitterion
  • Primary alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
logP6.65ALOGPS
logP6.24ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)13.34ChemAxon
pKa (Strongest Basic)-1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area163.65 ŲChemAxon
Rotatable Bond Count24ChemAxon
Refractivity162.08 m³·mol⁻¹ChemAxon
Polarizability66.39 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityNoChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M-2H]-266.8930932474
DeepCCS[M+Na]+243.39530932474

Predicted Retention Times

Underivatized

Chromatographic MethodRetention TimeReference
Predicted by Siyang on May 30, 202222.472 minutes33406817
Predicted by Siyang using ReTip algorithm on June 8, 20222.29 minutes32390414

Predicted Kovats Retention Indices

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #2CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C124890.0Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #2CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C124562.6Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #2CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C126516.7Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #4CCCCCCCCCCCCCC=CC(O)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C4846.3Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #4CCCCCCCCCCCCCC=CC(O)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C4481.5Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,1TMS,isomer #4CCCCCCCCCCCCCC=CC(O)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C6246.1Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #3CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C4697.7Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #3CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C4380.2Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #3CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C5761.8Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #5CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C4684.6Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #5CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C4440.0Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #5CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C5865.1Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #6CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C4662.7Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #6CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C4441.0Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TMS,isomer #6CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C5905.1Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #1CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C4726.1Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #1CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C4484.8Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #1CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C5716.9Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #2CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C4594.7Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #2CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C4310.9Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #2CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C5396.8Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #3CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C4625.1Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #3CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C4351.1Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #3CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C5481.9Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #4CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C4610.1Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #4CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C4393.0Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,3TMS,isomer #4CCCCCCCCCCCCCC=CC(O)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C5599.5Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,4TMS,isomer #1CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C4626.6Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,4TMS,isomer #1CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C4301.4Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,4TMS,isomer #1CCCCCCCCCCCCCC=CC(O[Si](C)(C)C)C(CO[Si](C)(C)C)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C)[Si](C)(C)C5152.3Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #2CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C5184.2Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #2CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C4804.1Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #2CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)N(C(=O)CCCCCNC1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C5961.1Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #3CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C5112.2Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #3CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C4711.0Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #3CCCCCCCCCCCCCC=CC(O[Si](C)(C)C(C)(C)C)C(CO)NC(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C5702.4Standard polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #6CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C5111.3Semi standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #6CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C4744.1Standard non polar33892256
N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide,2TBDMS,isomer #6CCCCCCCCCCCCCC=CC(O)C(CO)N(C(=O)CCCCCN(C1=CC=C([N+](=O)[O-])C2=NON=C12)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C5846.4Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TMS_1_1) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TMS_1_3) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TMS_2_1) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TMS_2_2) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TMS_2_4) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_1_1) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_1_2) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_1_3) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_1_4) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_2_1) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_2_4) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide GC-MS (TBDMS_2_5) - 70eV, PositiveNot Available2021-11-03Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 10V, Positive-QTOFsplash10-000i-0090000000-61acfb5ae30ad3f4c5b02021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 20V, Positive-QTOFsplash10-01p9-0090000000-32d518e14392270400a72021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 40V, Positive-QTOFsplash10-03gi-0090000000-cd354d61a6e6e34044502021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 10V, Positive-QTOFsplash10-0006-0090000000-c40e106c8c737ae3143b2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 20V, Positive-QTOFsplash10-0006-0090000000-c40e106c8c737ae3143b2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 40V, Positive-QTOFsplash10-001i-0090000000-dc742cc31e628e6617f02021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 10V, Negative-QTOFsplash10-004i-0000090000-e1c44efdf24304d6e3192021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 20V, Negative-QTOFsplash10-004i-0010090000-49766feff9cae7a129162021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - N-[(Z)-1,3-Dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide 40V, Negative-QTOFsplash10-004o-0040090000-d250777c793af06085272021-10-12Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen Locations
  • Blood
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedNot SpecifiedNot SpecifiedNormal details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID110489
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem Compound123968
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Barupal DK, Fiehn O: Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach. Environ Health Perspect. 2019 Sep;127(9):97008. doi: 10.1289/EHP4713. Epub 2019 Sep 26. [PubMed:31557052 ]